Cargando…
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer
The downstream targets of hypoxia inducible factor-1 alpha (HIF-1α) play an important role in tumor progression and angiogenesis. Therefore, inhibition of HIF-mediated transcription has potential in the treatment of cancer. One attractive strategy for inhibiting HIF activity is the disruption of the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113146/ https://www.ncbi.nlm.nih.gov/pubmed/24775564 http://dx.doi.org/10.1186/1476-4598-13-91 |
_version_ | 1782328251635466240 |
---|---|
author | Reece, Kelie M Richardson, Emily D Cook, Kristina M Campbell, Tessa J Pisle, Stephen T Holly, Alesia J Venzon, David J Liewehr, David J Chau, Cindy H Price, Douglas K Figg, William D |
author_facet | Reece, Kelie M Richardson, Emily D Cook, Kristina M Campbell, Tessa J Pisle, Stephen T Holly, Alesia J Venzon, David J Liewehr, David J Chau, Cindy H Price, Douglas K Figg, William D |
author_sort | Reece, Kelie M |
collection | PubMed |
description | The downstream targets of hypoxia inducible factor-1 alpha (HIF-1α) play an important role in tumor progression and angiogenesis. Therefore, inhibition of HIF-mediated transcription has potential in the treatment of cancer. One attractive strategy for inhibiting HIF activity is the disruption of the HIF-1α/p300 complex, as p300 is a crucial coactivator of hypoxia-inducible transcription. Several members of the epidithiodiketopiperazine (ETP) family of natural products have been shown to disrupt the HIF-1α/p300 complex in vitro; namely, gliotoxin, chaetocin, and chetomin. Here, we further characterized the molecular mechanisms underlying the antiangiogenic and antitumor effects of these ETPs using a preclinical model of prostate cancer. In the rat aortic ring angiogenesis assay, gliotoxin, chaetocin, and chetomin significantly inhibited microvessel outgrowth at a GI(50) of 151, 8, and 20 nM, respectively. In vitro co-immunoprecipitation studies in prostate cancer cell extracts demonstrated that these compounds disrupted the HIF-1α/p300 complex. The downstream effects of inhibiting the HIF-1α/p300 interaction were evaluated by determining HIF-1α target gene expression at the mRNA and protein levels. Dose-dependent decreases in levels of secreted VEGF were detected by ELISA in the culture media of treated cells, and the subsequent downregulation of VEGFA, LDHA, and ENO1 HIF-1α target genes were confirmed by semi-quantitative real-time PCR. Finally, treatment with ETPs in mice bearing prostate tumor xenografts resulted in significant inhibition of tumor growth. These results suggest that directly targeting the HIF-1α/p300 complex with ETPs may be an effective approach for inhibiting angiogenesis and tumor growth. |
format | Online Article Text |
id | pubmed-4113146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41131462014-07-29 Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer Reece, Kelie M Richardson, Emily D Cook, Kristina M Campbell, Tessa J Pisle, Stephen T Holly, Alesia J Venzon, David J Liewehr, David J Chau, Cindy H Price, Douglas K Figg, William D Mol Cancer Research The downstream targets of hypoxia inducible factor-1 alpha (HIF-1α) play an important role in tumor progression and angiogenesis. Therefore, inhibition of HIF-mediated transcription has potential in the treatment of cancer. One attractive strategy for inhibiting HIF activity is the disruption of the HIF-1α/p300 complex, as p300 is a crucial coactivator of hypoxia-inducible transcription. Several members of the epidithiodiketopiperazine (ETP) family of natural products have been shown to disrupt the HIF-1α/p300 complex in vitro; namely, gliotoxin, chaetocin, and chetomin. Here, we further characterized the molecular mechanisms underlying the antiangiogenic and antitumor effects of these ETPs using a preclinical model of prostate cancer. In the rat aortic ring angiogenesis assay, gliotoxin, chaetocin, and chetomin significantly inhibited microvessel outgrowth at a GI(50) of 151, 8, and 20 nM, respectively. In vitro co-immunoprecipitation studies in prostate cancer cell extracts demonstrated that these compounds disrupted the HIF-1α/p300 complex. The downstream effects of inhibiting the HIF-1α/p300 interaction were evaluated by determining HIF-1α target gene expression at the mRNA and protein levels. Dose-dependent decreases in levels of secreted VEGF were detected by ELISA in the culture media of treated cells, and the subsequent downregulation of VEGFA, LDHA, and ENO1 HIF-1α target genes were confirmed by semi-quantitative real-time PCR. Finally, treatment with ETPs in mice bearing prostate tumor xenografts resulted in significant inhibition of tumor growth. These results suggest that directly targeting the HIF-1α/p300 complex with ETPs may be an effective approach for inhibiting angiogenesis and tumor growth. BioMed Central 2014-04-28 /pmc/articles/PMC4113146/ /pubmed/24775564 http://dx.doi.org/10.1186/1476-4598-13-91 Text en Copyright © 2014 Reece et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Reece, Kelie M Richardson, Emily D Cook, Kristina M Campbell, Tessa J Pisle, Stephen T Holly, Alesia J Venzon, David J Liewehr, David J Chau, Cindy H Price, Douglas K Figg, William D Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer |
title | Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer |
title_full | Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer |
title_fullStr | Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer |
title_full_unstemmed | Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer |
title_short | Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer |
title_sort | epidithiodiketopiperazines (etps) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the hif-1α/p300 complex in a preclinical model of prostate cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113146/ https://www.ncbi.nlm.nih.gov/pubmed/24775564 http://dx.doi.org/10.1186/1476-4598-13-91 |
work_keys_str_mv | AT reecekeliem epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT richardsonemilyd epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT cookkristinam epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT campbelltessaj epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT pislestephent epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT hollyalesiaj epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT venzondavidj epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT liewehrdavidj epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT chaucindyh epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT pricedouglask epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer AT figgwilliamd epidithiodiketopiperazinesetpsexhibitinvitroantiangiogenicandinvivoantitumoractivitybydisruptingthehif1ap300complexinapreclinicalmodelofprostatecancer |